The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer

The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations remains unclear. We conducted a retrospective cohort study using data from the claims database of Taip...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Vincent Yi-Fong, Yang, Kuang-Yao, Huang, Ting-Yu, Hsu, Chia-Chen, Chen, Yuh-Min, Yen, Jiin-Cherng, Chou, Yueh-Ching, Chang, Yuh-Lih, He, Chien-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486374/
https://www.ncbi.nlm.nih.gov/pubmed/32917914
http://dx.doi.org/10.1038/s41598-020-71583-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486374/
https://www.ncbi.nlm.nih.gov/pubmed/32917914
http://dx.doi.org/10.1038/s41598-020-71583-w

Ejemplares similares